NCT07064759Phase 3Recruiting

Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration

Study sponsor: 4D Molecular Therapeutics

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2028-11Estimated

Enrollment · participants480Estimated

Source updated2026-04-16Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2026-02-12 · 1 field changed

Enrollment · participant count

Recorded edit

− Previous value

count: 400; type: ESTIMATED

+ Updated value

count: 480; type: ESTIMATED

Check registry source

Posted 2025-10-20 · 1 field changed

Primary outcomes · main study measures

Text edit · unverified significance

− Previous value

measure: Mean change from baseline in BCVA ETDRS letter score at Week 52

+ Updated value

measure: Mean change from baseline in Best Corrected Visual Accuity (BCVA) Early Treatment for Diabetic Retinopathy (ETDRS) letter score at Week 52

The saved outcome text may be shortened. Check the source for full wording.

Check registry source